Marcio Souza, Praxis CEO
June 6, 2022 10:39 AM EDT
R&D

Prax­is nose­dives as an­ti­de­pres­sant ef­fort col­laps­es in PhII/III fail — lay­offs to fol­low

Max Gelman

Senior Editor

Prax­is shares $PRAX are tak­ing a tum­ble Mon­day af­ter the com­pa­ny re­port­ed its lead de­pres­sion drug failed a Phase II/III study, forc­ing a sub­stan­tial pipeline …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Some FDA med­ical de­vice staff re­in­stat­ed just days af­ter re­ceiv­ing pink slips

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Al­con tried to sink Au­ri­on's IPO in 'Valen­tine's Day mas­sacre,' new law­suits say

Pfiz­er hires ex-FDA deputy Pa­trizia Cavaz­zoni as chief med­ical of­fi­cer

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times